PharmaMar announces abstracts to be presented at ASCO 2023
May 29, 2023 at 10:28 am
Share
PharmaMar (MSE: PHM) has announced today that the Company and its partners will present seven new abstracts from several clinical trials with Zepzelca (lurbinectedin) and Yondelis (trabectedin) at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
The studies to be presented at the congress include two oral presentations with two PharmaMar compounds. With the abstract entitled: 'Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)', Gregory Cote, MD, PhD, medical oncologist at Massachusetts General Hospital, will present updated efficacy and tolerability data on the combination of lurbinectedin with doxorubicin from the phase 1B soft-tissue sarcoma study leading into a randomized phase II trial in leiomyosarcoma (LMS).
Peter Reichardt, MD, Physician-in-Chief of the Interdisciplinary Oncology Clinic HELIOS Klinikum Berlin-Buch, will present the abstract entitled: 'Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)', in which he will present efficacy and safety data of trabectedin plus nivolumab as second-line treatment for patients with metastatic or inoperable soft tissue sarcoma, previously treated with anthracyclines. The study confirms the activity of trabectedin plus nivolumab, particularly in patients with lipo- or leiomyosarcomas, suggesting synergistic activity. In addition, the safety of trabectedin and nivolumab was consistent with the safety profiles of each drug separately, with no new findings relevant to the combination.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 